| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Novartis AG | Asciminib (ASC) - (ASC2ESCALATE) | Chronic myeloid leukemia in chronic | NDA Filing | Ongoing | Oral | Oncology |
| Novartis AG | Pelacarsen - (Lp(a)FRONTIERS APHERESIS) | Cardiovascular disease | NDA Filing | Ongoing | Subcutaneous | Cardiology |
| Novartis AG | Kesimpta (ofatumumab) - (ARTIOS) | Relapsing multiple sclerosis (RMS) | NDA Filing | Data Released | Subcutaneous | Neurology |
| Novartis AG | KLU156 (GanLum) | Malaria | NDA Filing | Data Released | Intravenous | Antimalarial |
| Novartis AG | Piqray - (BYLieve) | Metastatic breast cancer (mBC) | NDA Filing | Data Released | Oral | Oncology |
| Novartis AG | Leqvio - (VICTORION-1P) | CVRR (Primary prevention) | Phase 3 | Ongoing | Subcutaneous injection | Cardiology |
| Novartis AG | Zigakibart (BION-1301) - (BEYOND) | IgA nephropathy | Phase 3 | Ongoing | Intravenous | #N/A |
| Novartis AG | MONJUVI (tafasitamab) - (frontMIND) | Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 3 | Ongoing | Intravenous | Oncology |